Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06042400 · ClinicalTrials.gov registry record · NA
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
A NA study, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT06042400 is a NA study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 30 participants.
The verdict
NCT06042400, a NA study, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.
Interventions
- BEHAVIORAL Written Exposure Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2023-09-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06042400
The ClinicalTrials.gov registry entry for NCT06042400 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Written Exposure Therapy is the first listed.
NCT06042400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06042400 about?
NCT06042400 is a clinical study titled "Trial of Written Exposure for Metastatic Cancer Patients (EASE)". In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer pati...
What is the current status of trial NCT06042400?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-04-18. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT06042400?
The interventions under investigation include: Written Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06042400?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.